Indeed, an early phase one study administering up to 1.8 × 1012 vg/kg AAV2-factor IX (fIX) into the skeletal muscle of hemophilia B patients demonstrated fIX expression levels above baseline in four out of eight participants despite the presence of pre-existing high titer NABs to AAV2 (46). Here, F9 is linked to hemophilia B.